Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 300 versus LIPIODOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 300 versus LIPIODOL.
IOPAMIDOL-300 vs LIPIODOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated contrast agent that attenuates X-rays, thereby enhancing radiographic visualization of vascular structures and organs. It does not bind to receptors and has no significant pharmacological activity.
Lipiodol is an iodinated ethyl ester of the fatty acids of poppyseed oil. It acts as a radiopaque contrast agent for imaging due to its iodine content, and in chemoembolization, it selectively accumulates in hepatocellular carcinoma (HCC) via tumor neovasculature and is retained due to lack of lymphatic drainage, allowing targeted delivery of chemotherapeutic agents.
Intravenous or intra-arterial administration; dose varies by procedure (e.g., 1-2 mL/kg for CT, up to 50-100 mL for angiography) up to a maximum of 200 mL per procedure.
Lymphangiography: 5-20 mL injected slowly into lymphatic vessels. Uterine/Fallopian tube imaging: 3-20 mL injected through cervix. Hepatic chemoembolization: 5-15 mL mixed with chemotherapeutic agents injected into hepatic artery.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >90 mL/min). In moderate renal impairment it extends to 3-5 hours; in severe renal impairment (CrCl <30 mL/min) it can exceed 30 hours, prolonging diagnostic window.
Terminal elimination half-life is approximately 50-60 days, reflecting slow clearance from lipid-rich tissues.
Primarily renal excretion of intact drug via glomerular filtration; >90% excreted unchanged in urine within 24 hours. Less than 1% fecal or biliary elimination.
Primarily eliminated via biliary/fecal route as unchanged drug; less than 1% excreted renally.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent